Drug intelligence / Profile preview

ADC 3

Development stage: Approved
Lead developer: Hexagon Bio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**ADC 3** is an undisclosed preclinical antibody-drug conjugate program from Hexagon Bio for solid tumors. Hexagon Bio publicly lists ADC 3 in its ADC pipeline, but has not disclosed its antibody target, linker, payload, molecular composition, route of administration, or dosage form. ([hexagonbio.com](https://www.hexagonbio.com/pipeline/))

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on ADC 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC 3.

Explore the full profile